Source: International Congress 2017 – PG6 Assessing and monitoring airway inflammation in asthma and chronic obstructive pulmonary disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Peter J. Barnes (London, United Kingdom). Overview and history of different ways of assessing and monitoring inflammatory airway diseases. International Congress 2017 – PG6 Assessing and monitoring airway inflammation in asthma and chronic obstructive pulmonary disease

Member's Comments

No comment yet.

Related content which might interest you: Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label Source: Eur Respir J, 51 (1) 1701817; 10.1183/13993003.01817-2017 Year: 2018 Assessing & monitoring airway diseases using biomarkers Source: ERS Course 2019 - Masterclass in airways disease 2019 Year: 2019 Potential use of artificial nose in diagnosis and monitoring of different lung diseases Source: Eur Respir J 2007; 30: Suppl. 51, 532s Year: 2007 Monitoring the inflammatory heterogeneity in asthma with multiple biomarkers for multidimensional endotyping Source: International Congress 2017 – "Alarming" immunological patterns in asthma Year: 2017 Measuring inflammation inpaediatric severe asthma: biomarkers in clinical practice Source: Breathe, 16 (1) 190301; 10.1183/20734735.0301-2019 Year: 2020 Investigation and assessment of airway and lung inflammation: we now have the tools, what are the questions? Source: Guideline 1998 Year: 1998 The role of cluster analysis in defining phenotypes of obstructive airway diseases: is there a need for a new taxonomy of obstructive airway diseases? Source: Annual Congress 2011 - PG11 Update of phenotypes of asthma and COPD Year: 2011 Domiciliary monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and/or progression: a systematic review Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives Source: Eur Respir Rev 2015; 24: 594-601 Year: 2015 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies Year: 2009 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment Year: 2009 Do allergic diseases and symptoms show the same pattern of genetic and environmental influences? Source: Eur Respir J 2002; 20: Suppl. 38, 119s Year: 2002 COPD as a lung disease with heterogeneous systemic inflammatory consequences: clinical impact Source: Research Seminar 2011 - Physical activity, nutritional status and systemic inflammation in COPD Year: 2011 Discrepancy of non-invasive inflammatory markers and lung function tests to current level of clinical control in childhood asthma Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma Year: 2009